Kite Pharma Plans Cell Therapy Manufacturing Facility

Published 5-6-2019

Kite Pharma is planning to build a biopharmaceutical manufacturing facility in Frederick, Md. Located on a 20-acre site at the Urbana Corporate Center, the project will provide 217,000 sf of manufacturing and support space for the production of chimeric antigen receptor T (CAR T) cell therapies as well as investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors. The facility will also include 62,000 sf of office space. Occupancy is expected in 2021. Kite is a subsidiary of Gilead Sciences.